Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 17 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Does aspirin prevent colorectal adenomas?

Two studies in this week's New England Journal of Medicine find that aspirin is associated with a reduction in the incidence of colorectal adenomas.

News image

fiogf49gjkf04

Experimental and observational studies suggest that regular aspirin use may decrease the risk of colorectal adenomas.

In this study, researchers from the United States conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas.

The research team randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo.

1 or more adenomas were found in 17% of patients in the aspirin group and in 27% in the placebo group.
New England Journal of Medicine

They determined the proportion of patients with adenomas, the number of recurrent adenomas, and the time to the development of adenoma between randomization and subsequent colonoscopic examinations.

The team adjusted relative risks for age, sex, cancer stage, the number of colonoscopic examinations, and the time to a first colonoscopy.

The study was terminated early by an independent data and safety monitoring board when statistically significant results were reported during a planned interim analysis.

The researchers determined that a total of 517 patients had at least 1 colonoscopic examination a median of 12.8 months after randomization.

The team found 1 or more adenomas in 17% of patients in the aspirin group and in 27% in the placebo group.

Furthermore, the mean number of adenomas was lower in the aspirin group than the placebo group (0.30 versus 0.49, respectively).

The team also found that the adjusted relative risk of any recurrent adenoma in the aspirin group, compared with the placebo group, was 0.65.

Additionally, the team found that the time to the detection of a first adenoma was longer in the aspirin group than in the placebo group.

Dr Robert Sandler’s team concluded, “Daily use of aspirin is associated with a significant reduction in the incidence of colorectal adenomas in patients with previous colorectal cancer”.

In a separate but related study in the same publication, researchers performed a randomized, double-blind trial of aspirin as a chemopreventive agent against colorectal adenomas.

They assigned 1121 patients with a recent history of histologically documented adenomas to receive placebo, 81 mg of aspirin, or 325 mg of aspirin daily.

According to the protocol, follow-up colonoscopy was to be performed approximately 3 years after the qualifying endoscopy.

The team compared the groups with respect to the risk of 1 or more neoplasms (adenomas or colorectal cancer) at least 1 year after randomization.

The researchers found that reported adherence to study medications, and avoidance of nonsteroidal anti-inflammatory drugs were both excellent.

They performed follow-up colonoscopy at least 1 year after randomization in 97% of patients.

The team found that the incidence of 1 or more adenomas was 47% in the placebo group, 38% in the 81-mg aspirin group, and 45% in the 325-mg aspirin group.

Unadjusted relative risks of any adenoma were 0.81 in the 81-mg group and 0.96 in the 325-mg group.

For advanced neoplasms, the team found that the respective relative risks were 0.59 and 0.83.

Dr John Baron’s team concluded, “Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel”.

New Engl J Med 2003; 348(10): 883-90, 891-99
07 March 2003

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us